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THYROID CANCER AND NODULES
Patients’ View on the Management of Papillary
Thyroid Microcarcinoma:
Active Surveillance or Surgery
Yusaku Yoshida, Kiyomi Horiuchi, and Takahiro Okamoto
Background: Clinical practice guidelines have endorsed both active surveillance and surgery as viable man-
agement options for papillary thyroid microcarcinoma (PTMC). However, patients’ perceptions on the options
have rarely been addressed.
Methods: A cross-sectional survey was conducted on 50 patients with PTMC who were under either active
surveillance (n = 20) or postoperative follow-up (n = 30). The primary outcome was anxiety, which was mea-
sured using the State-Trait Anxiety Inventory (STAI). A questionnaire that comprised six items about PTMC-
related symptoms and concerns, which were measured with a visual analog scale, was also administered.
Cohen’s d effect size was calculated to express group differences. Multiple regression analysis was used to
examine the relationships between state anxiety and other variables.
Results: The median age and observation period were 61.5 years (range, 40–83 years) and 4.1 years (range,
0–8.6 years), respectively. The female/male ratio was 38/12. Compared with the surgery group, the active
surveillance group showed higher scores in both state anxiety and trait anxiety, with corresponding effect sizes
of 0.55 (confidence interval [CI] -0.03 to 1.1; p = 0.068) and 0.63 (CI 0.02–1.2; p = 0.037), respectively. Trait
anxiety (b = 0.83) and observation time (b = -1.57) were the significant predictors of state anxiety. Moderate
effect sizes were observed for ‘‘discomfort in the neck’’ (-0.53; CI -1.11 to 0.04); ‘‘weak voice’’ (-0.46;
CI -1.03 to 0.12); and ‘‘nervous about neck appearance’’ (-0.64; CI -1.23 to -0.07), in favor of active
surveillance.
Conclusions: State anxiety among patients with PTMC seemed to be a reflection of an individual’s trait rather
than management. Understanding the patients’ view appears to be key to improve shared decision-making.
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Introduction
The incidence of thyroid cancer is increasing world-wide, including in Japan (1–3). This increase may
mostly be due to the growing number of incidental findings
encountered with the increasing use of regular health
checkups; screening tests such as ultrasound for carotid ar-
teriosclerosis or computed tomography scans for chest le-
sions, among others. Of these incidental findings, papillary
thyroid carcinoma (PTC) accounts for the majority of the
malignant lesions. PTC is generally characterized as a slow-
growing indolent tumor, which may not even be harmful, as
several studies demonstrated that PTC is frequently found on
autopsy (4–6). Davies and Welch further pointed out that
many of the newly diagnosed PTC patients had tumors
measuring £1 cm in diameter, hence papillary thyroid mi-
crocarcinoma (PTMC) (3).
Investigators at two institutes in Japan pioneered clinical
studies on the active surveillance of PTMC without lymph
node or distant metastasis (T1aN0M0) (7–9). Ito et al. fol-
lowed 1235 patients who did not undergo surgery for PMTC
and reported that 8.0% experienced a tumor enlargement by
‡3 mm in diameter, and 3.8% developed lymph node me-
tastasis 10 years after the first diagnosis (8). Sugitani and
colleagues observed 480 PMTC in 384 patients after a mean
follow-up of 6.8 years; they estimated that 7.3% of the lesions
had a probability of enlargement at 10 years after the diag-
nosis (9). Based on these findings, the Japanese Clinical
Department of Breast and Endocrine Surgery, Tokyo Women’s Medical University, Tokyo, Japan.
ª Yusaku Yoshida et al. 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the
Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncom-
mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
THYROID
Volume 30, Number 5, 2020
Mary Ann Liebert, Inc.
DOI: 10.1089/thy.2019.0420
681
Practice Guidelines for Thyroid Tumors introduced active
surveillance without surgery as one of the management op-
tions for PTMC (10,11), which was also recognized as an
alternative option in the revised guidelines by the American
Thyroid Association (12).
Patients on active surveillance can avoid risks of compli-
cations and late consequences associated with surgery, al-
though they may have concerns about disease progression
despite their involvement in the shared decision process. On
the contrary, those who underwent surgery may be assured
because they can be considered cured, yet they may experi-
ence sequelae due to the operation.
To clarify the concerns associated with the management of
PTMC from the patient’s perspective, we conducted a cross-
sectional study on the patient-reported outcomes of PTMC
managed with active surveillance or surgery.
Materials and Methods
Design and patients
A cross-sectional survey was conducted on patients with
PTMC who visited our outpatient clinic between September
1, 2016, and April 30, 2017. The study participants were
either on active surveillance or postoperative follow-up for
their PTMC, which was defined as measuring £1 cm in
maximum diameter, without any apparent lymph node or
distant metastases (T1aN0M0). The time of surgery was
limited to the period between January 2011 and December
2013 for patients who underwent an operation (surgery
group). In contrast, active surveillance was initiated between
January 2006 and December 2016 for those who remained
under follow-up without surgery (active surveillance group).
Observations and measurements
The primary outcome was anxiety, which was measured
using the new edition of the State-Trait Anxiety Inventory
(STAI) Form JYZ. The STAI was a self-administered instru-
ment with two subscales to separately assess anxiety-associated
conditions at a given time (state anxiety) and anxiety unique to
an individual’s personality (trait anxiety) (13,14). The inventory
has 20 items for each subscale, with a 4-point Likert scale from
‘‘almost never’’ to ‘‘almost always.’’ Therefore, the possible
scores for each domain can range from a minimum of 20 to a
maximum of 80. Test/retest correlation coefficients were re-
ported to vary from 0.31 to 0.86, and internal consistency alpha
coefficients were quite high, ranging from 0.86 to 0.95 (15).
The secondary outcomes were symptoms and concerns
related to PTMC. A questionnaire that was explicitly devel-
oped to measure the outcomes of this study included six
questions, as follows: (1) ‘‘Do you have any discomfort in
your neck?’’ (2) ‘‘Are you satisfied with the course of the
current cancer treatment or active surveillance?’’ (3) ‘‘Do
you feel anxious about the disease?’’ (4) ‘‘Do you have
trouble with swallowing?’’ (5) ‘‘Do you have a weak voice?’’
and (6) ‘‘Are you nervous about the appearance of your
neck?’’ Items 1, 3, 4, and 5 were adopted and modified from
the items in the thyroid cancer quality-of-life (THYCA-QoL)
instrument, a disease-specific health-related quality-of-life
questionnaire for thyroid cancer survivors (16). Since our
intention was not to measure the same property (quality of
life) of patients with PTMC, other items from THYCA-QoL
were not adopted, while items 2 and 6 were questions that
were specifically added. The patients were asked to respond
to each item using a visual analog scale (VAS) to evaluate
how they felt at the time of the survey; the VAS ranged from 0
(‘‘not at all’’) to 100 (‘‘very much so’’). Consented patients
were asked to complete the questionnaires immediately after
the office visits for medical examination.
The following demographic variables, as well as disease-
related data, were collected from the electronic medical re-
cords of each participant: age, sex, diagnosis, TNM staging,
and observation duration. Time zero was defined as the day of
surgery for the surgery group, and the day of shared decision-
making on nonoperative management for the active surveil-
lance group. The extent of thyroidectomy and lymph node
dissection, as well as surgical complications, was ascertained
for each case in the surgery group.
FIG. 1. Selection of study participants.
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Statistical analyses
The demographic and outcomes data between the active
surveillance and surgery groups were compared using the
Fisher’s exact test for categorical variables and either the
Student’s t-test or the Wilcoxon rank-sum test for continuous
variables. For comparisons of numerical data, the assump-
tions of Gaussian distribution and homoscedasticity were
examined by the Shapiro–Wilk test and the F-test, respec-
tively. The between-group differences in the STAI and VAS
scores were expressed by Cohen’s d effect size, in which the
mean difference in scores was divided by the pooled standard
deviation (SD). An effect size of 0.2 was considered small;
0.5 was considered moderate; and 0.8 was considered large
(17,18). Multiple linear regression analyses were used to
explore the associations between state anxiety and other
variables. Since our primary interest was the relationship
between anxiety (state anxiety) and management, we initially
constructed the hierarchically well-formulated model, with
state anxiety as the dependent variable and age, group, ob-
servation period, and trait anxiety as the explanatory vari-
ables, as well as their interaction terms with a group (19,20).
All analyses were performed using JMP Pro version 14 (SAS
Institute, Inc., Cary, NC). A two-tailed p-value of <0.05 was
considered statistically significant.
Ethical considerations
The study was approved by the Ethics Committee of
Tokyo Women’s Medical University (No. 4070). Each pa-
tient provided written informed consent before participating
in the study.
Results
Seventy-four potentially eligible patients visited the
outpatient clinic during the survey period. Nine patients did
not have the opportunity of being asked to participate in
the survey. Among 65 patients to whom the nature of the
study was explained, 56 patients consented to participate.
Valid responses were obtained from 20 patients in the ac-
tive surveillance group and 30 patients in the surgery group
(Fig. 1).
Patient characteristics
As shown in Table 1, 80% of the active surveillance group
and 73% of the surgery group were women. The median age
and observation period were 61.0 years (range, 42–83 years)
and 4.05 years (range, 0–8.6 years), respectively, in the active
surveillance group; and 62.5 years (range, 40–76 years) and
4.25 years (range, 2.8–6.2 years), respectively, in the surgery
group. There were no apparent differences in the distributions
of these variables between the groups. Multicentric PTMC
was more frequent in the surgery group (20%) than in the
active surveillance group (5%), although the difference was
not statistically significant ( p = 0.21). As for the extent of
thyroidectomy in the surgery group, lobectomy was carried
out for 24 patients (80%), including 2 patients with multi-
centric disease. All of the patients in the surgery group also
underwent prophylactic pre- and paratracheal lymph node
dissection. None of the patients experienced disease pro-
gression (active surveillance group) or relapse of the disease
(surgery group).
Anxiety
The mean – SD of the state anxiety score was higher in the
active surveillance group (41.3 – 11.1) than in the surgery
group (35.9 – 9.1), although the difference was not statisti-
cally significant ( p = 0.068), and its effect size was 0.55 with
a 95% confidence interval (CI) between -0.03 and 1.1. Trait
anxiety score (mean – SD) was 41.2 – 10.3 in the active sur-
veillance group and 35.2 – 9.0 in the surgery group
( p = 0.037), and its effect size was 0.63 (CI 0.05, 1.2)











Sex: (female/male) 16/4 22/8 0.74
Tumor size (mm):
median (range)
7.5 (4–10) 8 (4–10) 0.12
Multicentric 1 6 0.21

























PTMC, papillary thyroid microcarcinoma; TSH, thyrotropin.
Table 2. State–Trait Anxiety Inventory Scores
Active surveillance (n = 20) Surgery (n = 30) Effect size p
State anxiety 41.3 (11.1) 35.9 (9.1) 0.55 (-0.03 to 1.1) 0.068
Trait anxiety 41.2 (10.3) 35.2 (9.0) 0.63 (0.05 to 1.2) 0.037
STAI scores were expressed as mean (SD). The numbers in parentheses represent a 95% confidence interval.
SD, standard deviation; STAI, State-Trait Anxiety Inventory.
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(Table 2). Female patients in the active surveillance group
showed higher scores in state anxiety, compared with those in
the surgery group (effect size 0.69 CI 0.02–1.3); whereas
male patients exhibited no apparent difference in the scores
between the groups (effect size -0.15; CI -1.4 to 1.0) (Fig. 2).
The distributions and correlation coefficients of age, obser-
vation period, state anxiety score, and trait anxiety score are
shown in Figure 3. State anxiety score was significantly as-
sociated with trait anxiety score (Pearson’s r = 0.78, p < 0.01).
Multiple regression analyses with and without interaction
terms indicated that there was no significant interaction
(multiple-partial F test, F4, 40, 0.95 = 0.34, p > 0.05). The
model without interaction terms (F5, 44 = 20.2, p < 0.01,
R2 = 0.70) showed that the group variable was not associated
with state anxiety, while trait anxiety was positively
(b = 0.83, p < 0.001) and observation time was negatively
(b = -1.57, p = 0.003) associated with the outcome (Table 3).
Symptoms and concerns related to PTMC
As shown in Figure 4, the estimated effect size, based on
the responses on the VAS, was -0.53 (CI -1.11 to 0.04) for
‘‘discomfort in the neck’’; -0.36 (CI -0.92, 0.21) for ‘‘sat-
isfied with the clinical management’’; 0.3 (CI -0.26 to 0.88)
for ‘‘anxious about the disease’’; 0.08 (CI -0.49 to 0.64) for
‘‘troubles with swallowing’’; and -0.46 (CI -1.03 to 0.12) for
‘‘weak voice.’’ The group difference reached a statistically
significant level only for ‘‘nervous about neck appearance,’’
with an effect size of -0.64 (CI -1.23 to -0.07).
Discussion
Patient view or quality of life has been recognized as an
important outcome in clinical studies, as well as in daily
practice. Short-term health-related quality of life among
FIG. 2. State and trait anxiety scores by sex and management. AS, active surveillance; F, female patients; M, male
patients.
FIG. 3. Scatter plot matrix of age, observation years, state
anxiety score, and trait anxiety score (r: Pearson’s correla-
tion coefficient).
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thyroid cancer survivors is affected by surgery, thyroid
hormone withdrawal for radioactive iodine treatment, and
thyrotropin suppression therapy; in contrast, the results for
long-term survivors have been contradicting (21). In their
cohort of patients with differentiated thyroid carcinoma,
Hedman et al. reported that 48% of the participants con-
tinued to have concerns about having a recurrence, even
after 14–17 years after the diagnosis, although the investi-
gators also observed, in 89% of the survivors, that the dis-
ease did not influence their view on life (22). Sawka et al.
found that even low-risk thyroid cancer survivors, to some
extent, had concerns and unmet information needs about the
disease, which may impact their daily life (23–25).
However, concerning the management of PTMC, relevant
studies and clinical practice guidelines have focused on the
natural history of the tumor itself (i.e., disease progression)
and none had looked into the patients’ view on being man-
aged by either active surveillance or surgical treatment in the
manner of the present study. Davies et al. recently reported
their qualitative study that addressed patient experiences of
243 patients with PTMC (26). Thirty-seven percent of re-
spondents described their worry about cancer as occurring
sometimes or more frequently, but 60% said their worry was
less than it was when they first found out about their cancer.
Moreover, 83% of respondents agreed that undergoing active
surveillance was the best decision (26). Compared with that
study, our present investigation is unique because we had a
surgical group for comparison (27). We observed that the
state anxiety score was higher in the active surveillance group
than that in the surgery group. Although the difference did not
reach statistical significance, its effect size (0.55) was large
enough to be clinically meaningful. Patients in the active
surveillance group also exhibited higher scores for trait
anxiety compared with those in the surgery group resulting in
an effect size of 0.63, which was statistically and clinically
significant. Multiple regression analysis showed that trait
anxiety and observation time are independent predictors of
state anxiety, regardless of the management. The group dif-
ference in trait anxiety seemed to have been reflected in the
group difference in state anxiety. In other words, patient traits
predisposing to feel anxiety may explain the group difference
in state anxiety rather than the management itself.
Another unique attempt in this study was to measure the
symptoms and concerns related to the management of PTMC.
Moderate effect sizes associated with a preference for surgery
consisted of being ‘‘anxious about the disease,’’ whereas
those in favor of active surveillance mentioned ‘‘discomfort
in the neck,’’ ‘‘weak voice,’’ and ‘‘neck appearance.’’ These
observations were valuable lessons for us because we ex-
pected that our operative approach of using minimal expo-
sure (i.e., lobectomy along with paratracheal lymph node
dissection) and neuromonitoring devices in most patients
would have a low likelihood of causing any burden to the
patients. Investigators from the University of Wisconsin
reported that patient-perceived voice changes were fre-
quent (57%) after thyroidectomy, even in the absence of
vocal cord paralysis (28), and that 80% of patients had at
least one swallowing-related symptom (29). Physicians
have underestimated the prevalence of physical symptoms
associated with thyroid cancer treatments (30).
A few limitations need to be considered when interpreting
our findings. First, the timing of administering the question-
naires might affect the results. The participants likely had the
Table 3. Multiple Regression Analysis with State






Intercept 5.76 6.21 0.36
Trait anxiety score 0.83 0.09 <0.0001
Age (years) 0.09 0.08 0.26





Observation time (years) -1.57 0.51 0.003
R2 = 0.70.
FIG. 4. Effect size of management on symptoms and concerns related to PTMC measured by visual analog scales. PTMC,
papillary thyroid microcarcinoma.
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least anxiety because they were just assured that there was no
progression or recurrence of their disease by medical exami-
nation. Second, patients’ anxiety might also be explained by
other factors such as variations in the ways that physicians
provided explanations to the patients, as well as in the clinical
management strategies, such as follow-up examinations dur-
ing the postoperative observational period (31). Finally, the
study was underpowered to detect a clinically meaningful
difference in some of the effect sizes because of the limited
number of patients under active surveillance who were avail-
able for the survey.
Active surveillance may be a viable or even a desirable
option for PTMC, and its indications have been expanding to
include larger tumors (32,33). Understanding the patients’
view is critical to convey information and use appropriate
words in physician/patient communication to improve shared
decision-making (30,34).
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